NeOnc Technologies Holdings, Inc.
NGM: NTHILive Quote
📈 ZcoreAI Score
Our AI model analyzes NeOnc Technologies Holdings, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get NTHI Z-Score →About NeOnc Technologies Holdings, Inc.
Healthcare
Biotechnology
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
📊 Fundamental Analysis
NeOnc Technologies Holdings, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -100.0% revenue growth, which is negative, indicating a recent decline in revenue.
At a current price of $5.44, NTHI currently sits at the 23rd percentile of its 52-week range (Range: $3.20 - $12.99).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Revenue Growth
Weak
Key Financials
Market Cap
$133.32M
Trailing P/E
--
Forward P/E
-3.68
Beta (5Y)
--
52W High
$12.99
52W Low
$3.20
Avg Volume
52K
Day High
Day Low